Myanmar

Support for Vaccine: Measles Rubella
This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Myanmar
2. Vaccine grant number: 19-MMR-34a-X, 19-MMR-35a-Y
3. Date of Decision Letter: 20 May 2019
4. Date of the Partnership Framework Agreement: 4 April 2014
5. Programme title: New Vaccine Support (NVS), Measles Rubella, Follow-up campaign
6. Vaccine type: Measles Rubella
7. Requested product presentation and formulation of vaccine:
   Measles Rubella, 10 dose(s) per vial, LYOPHILISED
8. Programme Duration: 2019
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement)

<table>
<thead>
<tr>
<th>Programme Budget (US$)</th>
<th>&lt;=2018</th>
<th>2019</th>
<th>2020</th>
<th>2021</th>
<th>2022</th>
<th>2023</th>
<th>Total^2</th>
</tr>
</thead>
<tbody>
<tr>
<td>n/a</td>
<td>3,248,500</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>3,248,500</td>
</tr>
</tbody>
</table>

10. Vaccine introduction grant
    Not applicable

11. Product switch grant
    Not applicable

12. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement)

<table>
<thead>
<tr>
<th>Type of supplies to be purchased with Gavi funds</th>
<th>0-2018</th>
<th>2019</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of vaccine doses</td>
<td>4,989,700</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Annual Amounts (US$)</td>
<td>n/a</td>
<td>3,248,500</td>
<td>-</td>
</tr>
</tbody>
</table>

13. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.

14. Self-procurement: Not applicable

15. Co-financing obligations:

^1This is the entire duration of the Programme.
^2This is the total amount endorsed by Gavi for the entire duration of the Programme.
According to the co-financing policy, the Country falls within the group: Preparatory transition phase

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

<table>
<thead>
<tr>
<th>Type of supplies to be purchased with Country funds in each year</th>
<th>2019</th>
<th>2020</th>
<th>2021</th>
<th>2022</th>
<th>2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of vaccine doses</td>
<td>262,700</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Number of AD syringes</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Number of re-constitution syringes</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Number of safety boxes</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Value of vaccine doses (US$)</td>
<td>168,072</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Total co-financing payments (US$) (including freight)</td>
<td>171,000</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

16. Operational support for catch-up campaigns:

<table>
<thead>
<tr>
<th>Year</th>
<th>Grant Number</th>
<th>Amount US$</th>
</tr>
</thead>
<tbody>
<tr>
<td>2019</td>
<td>19-MMR-35a-Y</td>
<td>2,602,452</td>
</tr>
</tbody>
</table>

17. Additional Reporting Requirements:

To prepare for the annual procurement of vaccines, Country shall submit the following information each year:

- vaccine stock levels including buffer stock, by end of March;
- number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May.
- Countries shall report the actual switch date in the first renewal request following the actual implementation.

To be agreed with Gavi Secretariat

Due dates:
- 31 March 2019
- 15 May 2019
- N/A

In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.

18. Financial clarifications:

Country shall provide the following clarifications to Gavi:

Not applicable

* Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements.
19. Other conditions:
   Not applicable

Signed by,
On behalf of Gavi

Barry Greene
Managing Director
Finance & Operations
The GAVI Alliance

Hind Khatib-Othman

20 May 2019